ESPR Esperion Therapeutics, Inc.

Nasdaq esperion.com


$ 2.66 $ 0.16 (6.4 %)    

Friday, 07-Nov-2025 16:56:48 EST
QQQ $ 612.14 $ 1.56 (0.26 %)
DIA $ 470.45 $ 1.64 (0.35 %)
SPY $ 672.31 $ 2.95 (0.44 %)
TLT $ 89.45 $ -0.19 (-0.21 %)
GLD $ 367.77 $ 0.35 (0.1 %)
$ 2.66
$ 2.50
$ 2.64 x 100
$ 2.69 x 24
$ 2.49 - $ 2.67
$ 0.69 - $ 3.94
6,594,939
na
635.91M
$ 1.20
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 08-13-2025 06-30-2025 10-Q
3 05-08-2025 03-31-2025 10-Q
4 03-07-2025 01-01-1970 10-K
5 11-07-2024 09-30-2024 10-Q
6 08-12-2024 06-30-2024 10-Q
7 05-07-2024 03-31-2024 10-Q
8 02-27-2024 12-31-2023 10-K
9 11-07-2023 09-30-2023 10-Q
10 08-01-2023 06-30-2023 10-Q
11 05-09-2023 03-31-2023 10-Q
12 02-21-2023 12-31-2022 10-K
13 11-01-2022 09-30-2022 10-Q
14 08-02-2022 06-30-2022 10-Q
15 05-03-2022 03-31-2022 10-Q
16 02-22-2022 12-31-2021 10-K
17 11-02-2021 09-30-2021 10-Q
18 08-03-2021 06-30-2021 10-Q
19 05-04-2021 03-31-2021 10-Q
20 02-23-2021 12-31-2020 10-K
21 11-02-2020 09-30-2020 10-Q
22 08-10-2020 06-30-2020 10-Q
23 05-06-2020 03-31-2020 10-Q
24 02-27-2020 12-31-2019 10-K
25 11-06-2019 09-30-2019 10-Q
26 08-08-2019 06-30-2019 10-Q
27 05-08-2019 03-31-2019 10-Q
28 02-28-2019 12-31-2018 10-K
29 11-01-2018 09-30-2018 10-Q
30 08-02-2018 06-30-2018 10-Q
31 05-02-2018 03-31-2018 10-Q
32 02-20-2018 12-31-2017 10-K
33 11-07-2017 09-30-2017 10-Q
34 08-08-2017 06-30-2017 10-Q
35 05-04-2017 03-31-2017 10-Q
36 02-22-2017 12-31-2016 10-K
37 11-03-2016 09-30-2016 10-Q
38 08-04-2016 06-30-2016 10-Q
39 05-04-2016 03-31-2016 10-Q
40 02-25-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 esperion-therapeutics-q3-eps-016-misses-008-estimate-sales-87309m-beat-77803m-estimate

Esperion Therapeutics (NASDAQ:ESPR) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate ...

 esperion-nominates-esp-2001-as-preclinical-development-candidate-for-primary-sclerosing-cholangitis

– Highly-Specific Allosteric ACLY Inhibitor Designed to Target Liver and Bile Duct Injury, Inflammation, and Fibrosis Associate...

 esperion-announces-proposed-public-offering-of-common-stock-terms-not-disclosed

Esperion Therapeutics, Inc. ("Esperion") (NASDAQ:ESPR), a commercial stage biopharmaceutical company that focuses on de...

Core News & Articles

ANN ARBOR, Mich., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that it has entered into a settlemen...

 hc-wainwright--co-reiterates-buy-on-esperion-therapeutics-maintains-16-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Esperion Therapeutics (NASDAQ:ESPR) with a Buy and maintains $16...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION